- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging therapeutic agents for genitourinary cancers
Authors
Keywords
Renal cell carcinoma, Prostate cancer, Bladder cancer, Immunotherapy
Journal
Journal of Hematology & Oncology
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-09-04
DOI
10.1186/s13045-019-0780-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Autophagy inhibition to augment mTOR inhibition: A phase I/II trial of everolimus and hydroxychloroquine in patients with previously treated renal cell carcinoma
- (2019) Naomi B. Haas et al. CLINICAL CANCER RESEARCH
- PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer
- (2019) Elena Castro et al. JOURNAL OF CLINICAL ONCOLOGY
- BRCA2 and Other DDR Genes in Prostate Cancer
- (2019) Paz Nombela et al. Cancers
- Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer
- (2019) Patrick R. Halliday et al. Current Oncology Reports
- Current Status and Future Direction of Immunotherapy in Urothelial Carcinoma
- (2019) Michael Lattanzi et al. Current Oncology Reports
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2019) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Matthew Smith et al. LANCET ONCOLOGY
- EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC).
- (2019) Daniel Peter Petrylak et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab (pembro) and cabozantinib (cabo) in patients (pts) with metastatic renal cell carcinoma (mRCC): Phase I results.
- (2019) Molika Emmeline Keeler et al. JOURNAL OF CLINICAL ONCOLOGY
- Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
- (2019) Evan Y. Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.
- (2019) Orazio Caffo et al. JOURNAL OF CLINICAL ONCOLOGY
- Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma
- (2019) Jarred P. Reed et al. Expert Review of Anticancer Therapy
- PD-1/PD-L1 Combinations in Advanced Urothelial Cancer: Rationale and Current Clinical Trials
- (2019) Miles M. Hsu et al. Clinical Genitourinary Cancer
- Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma
- (2019) Matthew K. Labriola et al. Clinical Genitourinary Cancer
- Bladder Organoids and Spheroids: Potential Tools for Normal and Diseased Tissue Modelling
- (2019) IGOR VASYUTIN et al. ANTICANCER RESEARCH
- A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma
- (2019) Martin H. Voss et al. CANCER
- Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
- (2019) Karim Fizazi et al. LANCET ONCOLOGY
- Sex Differences in Tolerability to Anti‐Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non‐Small Cell Lung Cancer: Are We All Equal?
- (2019) Narjust Duma et al. ONCOLOGIST
- A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
- (2019) Salah-Eddine Bentebibel et al. Cancer Discovery
- EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors.
- (2019) Daniel Peter Petrylak et al. JOURNAL OF CLINICAL ONCOLOGY
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
- (2018) A R Hansen et al. ANNALS OF ONCOLOGY
- Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion
- (2018) Mario Mauthe et al. Autophagy
- Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics
- (2018) Serban Negoita et al. CANCER
- Discovery of Rogaratinib (BAY 1163877): a pan-FGFR Inhibitor
- (2018) Marie-Pierre Collin et al. ChemMedChem
- Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer
- (2018) Shilpa Gupta et al. CLINICAL CANCER RESEARCH
- Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
- (2018) Julius Strauss et al. CLINICAL CANCER RESEARCH
- Circulating Tumor DNA in Bladder Cancer: Novel Applications and Future Directions
- (2018) Manuel Caitano Maia et al. EUROPEAN UROLOGY
- Re: Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2018) Izak Faiena et al. EUROPEAN UROLOGY
- Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201)
- (2018) Hendrik Borgmann et al. EUROPEAN UROLOGY
- EV-103 study: A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer.
- (2018) Christopher J. Hoimes et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies.
- (2018) Rosa Maria Nadal et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
- (2018) Christos E. Kyriakopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)
- (2018) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer immunotherapy beyond immune checkpoint inhibitors
- (2018) Julian A. Marin-Acevedo et al. Journal of Hematology & Oncology
- Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
- (2018) Jun Guo et al. Journal of Hematology & Oncology
- Next generation of immune checkpoint therapy in cancer: new developments and challenges
- (2018) Julian A. Marin-Acevedo et al. Journal of Hematology & Oncology
- Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target
- (2018) Dongming Chen et al. JOURNAL OF MEDICAL GENETICS
- Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Noel Clarke et al. LANCET ONCOLOGY
- The long tail of oncogenic drivers in prostate cancer
- (2018) Joshua Armenia et al. NATURE GENETICS
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
- (2018) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recent developments in the treatment of advanced bladder cancer
- (2018) James Luke Godwin et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer
- (2018) Skyler B. Johnson et al. Current Oncology Reports
- Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma
- (2018) Kevin Zarrabi et al. Current Oncology Reports
- Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations
- (2018) Sumanta K. Pal et al. Cancer Discovery
- M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
- (2018) Karin M. Knudson et al. OncoImmunology
- Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
- (2018) Tara C. Mitchell et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).
- (2018) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC).
- (2018) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).
- (2018) Johann S. De Bono et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the IDO1 pathway in cancer: from bench to bedside
- (2018) Ming Liu et al. Journal of Hematology & Oncology
- Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler‐Weber‐Rendu Syndrome
- (2018) Andrew W. Hahn et al. ONCOLOGIST
- An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti‐Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma
- (2018) Toni K. Choueiri et al. ONCOLOGIST
- The Current and Evolving Landscape of First‐Line Treatments for Advanced Renal Cell Carcinoma
- (2018) Emiliano Calvo et al. ONCOLOGIST
- Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency
- (2018) Zafeiris Zafeiriou et al. EUROPEAN UROLOGY
- Renal cell carcinoma staging: pitfalls, challenges, and updates
- (2018) Sean R Williamson et al. HISTOPATHOLOGY
- Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing
- (2018) Zihai Li et al. Journal of Hematology & Oncology
- Dosimetry of Lu-177 PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pre-therapeutic imaging and “whole body” tumor dosimetry with treatment outcomes
- (2018) John A Violet et al. JOURNAL OF NUCLEAR MEDICINE
- Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy
- (2018) Adnan El-Achkar et al. Current Urology Reports
- Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial
- (2017) Patrick Schöffski et al. EUROPEAN JOURNAL OF CANCER
- Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer
- (2017) Matti Annala et al. EUROPEAN UROLOGY
- Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
- (2017) Sebastien Antoni et al. EUROPEAN UROLOGY
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
- (2017) Nicolas Mottet et al. EUROPEAN UROLOGY
- Emerging drugs for urothelial (bladder) cancer
- (2017) Kerwin Cumberbatch et al. EXPERT OPINION ON EMERGING DRUGS
- The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3
- (2017) Murali Janakiram et al. IMMUNOLOGICAL REVIEWS
- Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer
- (2017) John D. Norris et al. JOURNAL OF CLINICAL INVESTIGATION
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion
- (2017) Katherine S. Virgo et al. JOURNAL OF CLINICAL ONCOLOGY
- A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): Interim safety and clinical activity in patients with urothelial carcinoma.
- (2017) Daniel Peter Petrylak et al. JOURNAL OF CLINICAL ONCOLOGY
- New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy
- (2017) Kevin Zarrabi et al. Journal of Hematology & Oncology
- Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
- (2017) Daniel P Petrylak et al. LANCET
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
- (2017) Jianjun Gao et al. NATURE MEDICINE
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma
- (2017) Allison S. Betof et al. ONCOLOGIST
- A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer
- (2017) Grace A. Martin et al. PHARMACOTHERAPY
- Phase-III-Studie beim lokalen oder lokal fortgeschrittenen Prostatakarzinom
- (2017) H. Rexer et al. UROLOGE
- Phase-III-Studie beim lokalen oder lokal fortgeschrittenen Prostatakarzinom
- (2017) H. Rexer et al. UROLOGE
- CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8 + T Cell–Relevant Genes
- (2017) M. Angela Aznar et al. Cancer Immunology Research
- Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma
- (2017) Anna Laurell et al. Journal for ImmunoTherapy of Cancer
- Up-regulation of chemokine receptor CCR4 is associated with Human Hepatocellular Carcinoma malignant behavior
- (2017) Xi Cheng et al. Scientific Reports
- A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers
- (2016) K. N. Chi et al. ANNALS OF ONCOLOGY
- Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function
- (2016) A. G. de Vinuesa et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer
- (2016) Masanori Noguchi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
- (2016) P. M. Challita-Eid et al. CANCER RESEARCH
- Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies
- (2016) Senthamil R. Selvan et al. CURRENT CANCER DRUG TARGETS
- The evolving role of immunotherapy in prostate cancer
- (2016) Lisa M. Cordes et al. CURRENT OPINION IN ONCOLOGY
- Perioperative treatment and radical cystectomy for bladder cancer – a population based trend analysis of 10,338 patients in the Netherlands
- (2016) Tom J.N. Hermans et al. EUROPEAN JOURNAL OF CANCER
- Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer
- (2016) Edoardo Francini et al. EUROPEAN UROLOGY
- Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer
- (2016) Heather H. Cheng et al. EUROPEAN UROLOGY
- Recent developments in second and third line therapy of metastatic renal cell carcinoma
- (2016) Maria Giuseppa Vitale et al. Expert Review of Anticancer Therapy
- Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives
- (2016) Michael B. Atkins et al. JNCI-Journal of the National Cancer Institute
- IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
- (2016) Brian I Rini et al. LANCET ONCOLOGY
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
- (2016) Alain Ravaud et al. NEW ENGLAND JOURNAL OF MEDICINE
- Kinase Gene Expression Profiling of Metastatic Clear Cell Renal Cell Carcinoma Tissue Identifies Potential New Therapeutic Targets
- (2016) Pooja Ghatalia et al. PLoS One
- Nivolumab: The New Second Line Treatment for Advanced Renal-cell Carcinoma Commentary on: Nivolumab Versus Everolimus in Advanced Renal-cell Carcinoma
- (2016) Edmund C.P. Chedgy et al. UROLOGY
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- (2016) Jeffrey J. Wallin et al. Nature Communications
- Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives
- (2016) Michael B. Atkins et al. JNCI-Journal of the National Cancer Institute
- HER2 expression status in diverse cancers: review of results from 37,992 patients
- (2015) Min Yan et al. CANCER AND METASTASIS REVIEWS
- Clinical significance of the VEGF level in urinary bladder carcinoma
- (2015) Monica Sankhwar et al. Cancer Biomarkers
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- The Molecular Taxonomy of Primary Prostate Cancer
- (2015) Adam Abeshouse et al. CELL
- Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study
- (2015) Orazio Caffo et al. EUROPEAN UROLOGY
- Prospects for the future of prostate cancer vaccines
- (2015) Ravi A. Madan et al. Expert Review of Vaccines
- Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer
- (2015) Satoshi Nishiwada et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Application of Anti-CCR4 Monoclonal Antibody
- (2015) Ryuzo Ueda ONCOLOGY
- Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
- (2015) Asim Amin et al. Journal for ImmunoTherapy of Cancer
- Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model
- (2015) Howard I. Scher et al. PLoS One
- Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors
- (2014) Stephen W. Rafferty et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein
- (2014) M. Janakiram et al. CLINICAL CANCER RESEARCH
- Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial
- (2014) T. K. Choueiri et al. CLINICAL CANCER RESEARCH
- Radiotherapy for renal-cell carcinoma
- (2014) Gert De Meerleer et al. LANCET ONCOLOGY
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Thioredoxin Reductase 1 Expression and Castration-recurrent Growth of Prostate Cancer
- (2014) Swaroop S. Singh et al. Translational Oncology
- Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time
- (2013) Guillaume Ploussard et al. EUROPEAN UROLOGY
- Detection of circulating tumor cells in different stages of prostate cancer
- (2013) Mark Thalgott et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- PELP1: A review of PELP1 interactions, signaling, and biology
- (2013) Brian J. Girard et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity
- (2012) Timothy S. Fisher et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987
- (2012) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Alfons JM van den Eertwegh et al. LANCET ONCOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer
- (2011) Douglas G. McNeel et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Principles and Current Strategies for Targeting Autophagy for Cancer Treatment
- (2011) R. K. Amaravadi et al. CLINICAL CANCER RESEARCH
- Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer
- (2011) Gerhardt Attard et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy
- (2011) Matthew D Galsky et al. LANCET ONCOLOGY
- Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma
- (2010) Brian I. Rini et al. CANCER
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Structure−Activity Relationship for Thiohydantoin Androgen Receptor Antagonists for Castration-Resistant Prostate Cancer (CRPC)
- (2010) Michael E. Jung et al. JOURNAL OF MEDICINAL CHEMISTRY
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- The significance of OX40 and OX40L to T-cell biology and immune disease
- (2009) Michael Croft et al. IMMUNOLOGICAL REVIEWS
- Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial
- (2009) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
- (2008) R. Hu et al. CANCER RESEARCH
- Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma
- (2008) H. Huynh et al. CLINICAL CANCER RESEARCH
- Potential Impact of Postoperative Early Complications on the Timing of Adjuvant Chemotherapy in Patients Undergoing Radical Cystectomy: A High-Volume Tertiary Cancer Center Experience
- (2008) S. Machele Donat et al. EUROPEAN UROLOGY
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
- Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor
- (2008) Myles C. Hodgson et al. MOLECULAR CANCER THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now